Pneumocystis pneumonia in stage IIIA lung adenocarcinoma with immune-related acute kidney injury and thoracic radiotherapy: A case report

Table 1 Pneumocystis jirovecii pneumonia after steroid use due to immune-related adverse reactions

References	Country	Age and Sex	Cancer type	Patient condition	Treatment	AE and immunosuppression	Pathogens	Prognosis
Schwarz et al[23], 2019	Austria	79, Male	NSCLC	ECOG performance status 2, history of smoking, COPD	Chemotherapy-thoracic radiation-nivolumab	Immune-related pneumonitis, steroids for 6 weeks	Pneumocystis jirovecii	Died
		53, Male	NSCLC	ECOG performance status 0, history of smoking	Chemotherapy-thoracic radiation + nivolumab	Immune-related pneumonitis, steroids, and mycophenolate mofetil for 5 weeks	Pneumocystis jirovecii, cytomegalovirus	Died
Duarte et al[15], 2020	Belgium	68, Male	Melanoma	NA	Nivolumab-ipilimumab	Immune-related hepatitis and colitis, steroids for 10 weeks and infliximab	Pneumocystis jirovecii	Recovered
		24, Female	Hodgkin’s lymphoma	NA	Multi cycle chemotherapy-pembrolizumab	Macrophage-activating syndrome, steroids for 6 months	Pneumocystis jirovecii	Recovered
Arriola et al[24], 2015	England	69, Female	Melanoma	Chronic lymphocytic leukemia	Chemotherapy-ipilimumab	Immune-related colitis, steroids for 12 weeks, and infliximab	Pneumocystis jirovecii	Recovered
		63, Female	Melanoma	NA	Ipilimumab	A capillary leak syndrome, steroids for 4 weeks	Pneumocystis jirovecii	Recovered

NSCLC: Non-small cell lung cancer; ECOG: Eastern cooperative oncology group; COPD: Chronic obstructive pulmonary disease; AE: Adverse event; NA: Not available.